add directory ♦ physical therapy jobs
Related Topics:
Diagnostic RadiologyRadiology
Nuclear Pharmacy :: Pharmacy
Health Physics and Radiological Health :: Environmental Health
Today's News:
All Nuclear Medicine Jobs
Permanent Nuclear Medicine Job in Statewide Virginia with The Doctor Job
Looking for a job in a big city? Even if you've heard that a market is "saturated", we can help! Many job openings for physicians may be hidden and unavailable unless you know where to look. An excellent
Permanent Nuclear Medicine Job in Statewide Texas with The Doctor Job
Looking for a job in a big city? Even if you've heard that a market is "saturated", we can help! Many job openings for physicians may be hidden and unavailable unless you know where to look. An excellent
Permanent Nuclear Medicine Job in Statewide Pennsylvania with The Doctor Job
Looking for a job in a big city? Even if you've heard that a market is "saturated", we can help! Many job openings for physicians may be hidden and unavailable unless you know where to look. An excellent
PubMed: 0161-5505
Radiopharmaceuticals for nuclear cardiology: radiation dosimetry, uncertainties, and risk.
Stabin MG Related Articles Radiopharmaceuticals for nuclear cardiology: radiation dosimetry, uncertainties, and risk. J Nucl Med. 2008 Sep;49(9):1555-63 Authors: Stabin MG The technical basis for the dose estimates for several radiopharmaceuticals used in nuclear cardiology is reviewed, and cases in which uncertainty has been encountered in the dosimetry of an agent are discussed. Also discussed is the issue of uncertainties in radiation dose estimates and how to compare the relative risks of studies. METHODS: Radiation dose estimates (organ absorbed doses and effective doses) from different literature sources were directly compared. Typical values for administered activity per study were used to compare doses that are to be expected in clinical applications. RESULTS: The effective doses for all agents varied from 2 to 15 mSv per study, with the lowest values being seen for (13)N-NH(3) and (15)O-H(2)O studies and the highest values being seen for (201)Tl-chloride studies. The effective doses for (99m)Tc- and (201)Tl-labeled agents differed by about a factor of 2, a factor that is comparable to the uncertainty in individual values. This uncertainty results from the application of standard anthropomorphic and biokinetic models, presumably representative of the exposed population, to individual patients. CONCLUSION: Considerations such as diagnostic accuracy, ease of use, image quality, and patient comfort and convenience should generally dictate the choice of a radiopharmaceutical, with radiation dose being only a secondary or even tertiary consideration. Counseling of nuclear medicine patients who may be concerned about exposure should include a reasonable estimate of the median dose for the type of examination and administered activity of the radiopharmaceutical; in addition, it should be explained that the theoretic risks of the procedure are orders of magnitude lower than the actual benefits of the examination. Providing numeric estimates of risks from studies to individual patients is inappropriate, given the uncertainties in the dose estimates and the limited predictive power of current dose-risk models in the low-dose (i.e., diagnostic) range. PMID: 18765586 [PubMed - in process]
Bilateral Hilar Foci on 18F-FDG PET Scan in Patients Without Lung Cancer: Variables Associated with Benign and Malignant Etiology.
Karam M, Roberts-Klein S, Shet N, Chang J, Feustel P Related Articles Bilateral Hilar Foci on 18F-FDG PET Scan in Patients Without Lung Cancer: Variables Associated with Benign and Malignant Etiology. J Nucl Med. 2008 Sep;49(9):1429-1436 Authors: Karam M, Roberts-Klein S, Shet N, Chang J, Feustel P Bilateral hilar (18)F-FDG-avid foci are often noted on PET studies of patients without lung cancer. This finding may lead to diagnostic uncertainty about the presence of metastatic disease. Our objective was to evaluate features of these foci associated with benign or malignant etiology. METHODS: We performed a retrospective study of patients with cancer with bilateral hilar foci on 1 or 2 sequential (18)F-FDG PET studies between 2002 and 2006. Patients with lung cancer, sarcoidosis, or anthracosis/silicosis were excluded. Variables evaluated were maximum standard uptake values (SUV max), purity (absence of (18)F-FDG-avid foci in nonhilar mediastinal nodes), symmetry (difference between left and right side SUV max), the primary tumor, node size determined by CT, and, in those who participated in 2 studies, stability of uptake over time. The gold standard was histologic diagnosis or long-term clinical follow-up (range, 19-41 mo; mean, 25 mo). RESULTS: Fifty-one patients with the finding of bilateral hilar (18)F-FDG-avid foci underwent a staging-only PET study; 52 scans from an additional set of patients demonstrated this abnormality on at least 1 of 2 sequential studies, the first of which was performed for staging. On univariate analysis, variables associated with malignancy were SUV max (6.6 +/- 4.1 vs. 3.5 +/- 1.0 for benign, P < 0.001; t test); impurity (P < 0.001; chi(2) test), with 79% of impure scans versus 18% of pure scans being malignant; node size determined by CT (P = 0.027); and change in uptake between scans 1 and 2 (change in SUV = 2.7 +/- 2.1 vs. 0.73 +/- 1.1 for benign, P < 0.01; t test). Variables associated with benign etiology were: symmetry (difference between left and right sides = 0.57 +/- 0.54 for benign vs. 1.8 +/- 1.7 for malignant, P < 0.01), purity, and colorectal primary (75% of colorectal were benign vs. 34% of breast, 49% of lymphoma, and 37% of other, P = 0.030; chi(2) test). After multivariate analysis, SUV max and purity were found to be independent predictors, with the odds of malignancy increasing by 1.54 (95% confidence interval, 1.16-2.05) for each unit increase in SUV and decreasing by 0.08 (95% confidence interval, 0.03-0.22) if pure. CONCLUSION: In patients with nonlung cancer, in particular colorectal, foci of symmetric and mild uptake limited to the hilar regions that are stable on 2 sequential PET studies despite intervening anticancer therapy are likely related to a benign etiology. PMID: 18765585 [PubMed - as supplied by publisher]
Building a Foundation for Better PET Utilization.
Macapinlac H, Segall G Related Articles Building a Foundation for Better PET Utilization. J Nucl Med. 2008 Sep;49(9):46N-56N Authors: Macapinlac H, Segall G PMID: 18765584 [PubMed - in process]
Nuclear Medicine Communications - Current Table Of Contents
Tumor-specific activation of prodrugs: is there a role for nuclear medicine?
Page: 845DOI: 10.1097/MNM.0b013e3283094efcAuthors: Antunes, Ines F. a; Haisma, Hidde J. b; de Vries, Erik F.J. a
Imaging in cutaneous melanoma.
Page: 847DOI: 10.1097/MNM.0b013e32830439fbAuthors: Ho Shon, Ivan A. a b; Chung, David K.V. c d; Saw, Robyn P.M. d e; Thompson, John F. d e
Guidelines for imaging in cutaneous melanoma.
Page: 877DOI: 10.1097/MNM.0b013e3283043a0cAuthors: Ho Shon, Ivan A. a b; Chung, David K.V. c d; Saw, Robyn P.M. d e; Thompson, John F. d e
PubMed: 1532-6551
Letter to the editor.
Siddiqi S Related Articles Letter to the editor. J Nucl Cardiol. 2008 Sep-Oct;15(5):731; author reply 731-2 Authors: Siddiqi S PMID: 18761278 [PubMed - in process]
Reply.
Einstein AJ, Sanz J, Henzlova MJ, Dellegrottaglie S, Sirol M, Rajagopalan S Related Articles Reply. J Nucl Cardiol. 2008 Sep-Oct;15(5):731-2 Authors: Einstein AJ, Sanz J, Henzlova MJ, Dellegrottaglie S, Sirol M, Rajagopalan S PMID: 18761277 [PubMed - in process]
Noninvasive coronary angiography using multislice computed tomography in a patient with Amplatzer occluder.
Vallejo E, Pelaez JC, Quiroz O, Alcala B, Ramirez-Arias JL Related Articles Noninvasive coronary angiography using multislice computed tomography in a patient with Amplatzer occluder. J Nucl Cardiol. 2008 Sep-Oct;15(5):727-30 Authors: Vallejo E, Pelaez JC, Quiroz O, Alcala B, Ramirez-Arias JL PMID: 18761276 [PubMed - in process]
Subscribe to Nuclear_Medicine RSS feed 
Permanent Nuclear Medicine Job in Statewide Virginia with The Doctor Job
Looking for a job in a big city? Even if you've heard that a market is "saturated", we can help! Many job openings for physicians may be hidden and unavailable unless you know where to look. An excellent
Permanent Nuclear Medicine Job in Statewide Texas with The Doctor Job
Looking for a job in a big city? Even if you've heard that a market is "saturated", we can help! Many job openings for physicians may be hidden and unavailable unless you know where to look. An excellent
Permanent Nuclear Medicine Job in Statewide Pennsylvania with The Doctor Job
Looking for a job in a big city? Even if you've heard that a market is "saturated", we can help! Many job openings for physicians may be hidden and unavailable unless you know where to look. An excellent
PubMed: 0161-5505
Radiopharmaceuticals for nuclear cardiology: radiation dosimetry, uncertainties, and risk.
Stabin MG Related Articles Radiopharmaceuticals for nuclear cardiology: radiation dosimetry, uncertainties, and risk. J Nucl Med. 2008 Sep;49(9):1555-63 Authors: Stabin MG The technical basis for the dose estimates for several radiopharmaceuticals used in nuclear cardiology is reviewed, and cases in which uncertainty has been encountered in the dosimetry of an agent are discussed. Also discussed is the issue of uncertainties in radiation dose estimates and how to compare the relative risks of studies. METHODS: Radiation dose estimates (organ absorbed doses and effective doses) from different literature sources were directly compared. Typical values for administered activity per study were used to compare doses that are to be expected in clinical applications. RESULTS: The effective doses for all agents varied from 2 to 15 mSv per study, with the lowest values being seen for (13)N-NH(3) and (15)O-H(2)O studies and the highest values being seen for (201)Tl-chloride studies. The effective doses for (99m)Tc- and (201)Tl-labeled agents differed by about a factor of 2, a factor that is comparable to the uncertainty in individual values. This uncertainty results from the application of standard anthropomorphic and biokinetic models, presumably representative of the exposed population, to individual patients. CONCLUSION: Considerations such as diagnostic accuracy, ease of use, image quality, and patient comfort and convenience should generally dictate the choice of a radiopharmaceutical, with radiation dose being only a secondary or even tertiary consideration. Counseling of nuclear medicine patients who may be concerned about exposure should include a reasonable estimate of the median dose for the type of examination and administered activity of the radiopharmaceutical; in addition, it should be explained that the theoretic risks of the procedure are orders of magnitude lower than the actual benefits of the examination. Providing numeric estimates of risks from studies to individual patients is inappropriate, given the uncertainties in the dose estimates and the limited predictive power of current dose-risk models in the low-dose (i.e., diagnostic) range. PMID: 18765586 [PubMed - in process]
Bilateral Hilar Foci on 18F-FDG PET Scan in Patients Without Lung Cancer: Variables Associated with Benign and Malignant Etiology.
Karam M, Roberts-Klein S, Shet N, Chang J, Feustel P Related Articles Bilateral Hilar Foci on 18F-FDG PET Scan in Patients Without Lung Cancer: Variables Associated with Benign and Malignant Etiology. J Nucl Med. 2008 Sep;49(9):1429-1436 Authors: Karam M, Roberts-Klein S, Shet N, Chang J, Feustel P Bilateral hilar (18)F-FDG-avid foci are often noted on PET studies of patients without lung cancer. This finding may lead to diagnostic uncertainty about the presence of metastatic disease. Our objective was to evaluate features of these foci associated with benign or malignant etiology. METHODS: We performed a retrospective study of patients with cancer with bilateral hilar foci on 1 or 2 sequential (18)F-FDG PET studies between 2002 and 2006. Patients with lung cancer, sarcoidosis, or anthracosis/silicosis were excluded. Variables evaluated were maximum standard uptake values (SUV max), purity (absence of (18)F-FDG-avid foci in nonhilar mediastinal nodes), symmetry (difference between left and right side SUV max), the primary tumor, node size determined by CT, and, in those who participated in 2 studies, stability of uptake over time. The gold standard was histologic diagnosis or long-term clinical follow-up (range, 19-41 mo; mean, 25 mo). RESULTS: Fifty-one patients with the finding of bilateral hilar (18)F-FDG-avid foci underwent a staging-only PET study; 52 scans from an additional set of patients demonstrated this abnormality on at least 1 of 2 sequential studies, the first of which was performed for staging. On univariate analysis, variables associated with malignancy were SUV max (6.6 +/- 4.1 vs. 3.5 +/- 1.0 for benign, P < 0.001; t test); impurity (P < 0.001; chi(2) test), with 79% of impure scans versus 18% of pure scans being malignant; node size determined by CT (P = 0.027); and change in uptake between scans 1 and 2 (change in SUV = 2.7 +/- 2.1 vs. 0.73 +/- 1.1 for benign, P < 0.01; t test). Variables associated with benign etiology were: symmetry (difference between left and right sides = 0.57 +/- 0.54 for benign vs. 1.8 +/- 1.7 for malignant, P < 0.01), purity, and colorectal primary (75% of colorectal were benign vs. 34% of breast, 49% of lymphoma, and 37% of other, P = 0.030; chi(2) test). After multivariate analysis, SUV max and purity were found to be independent predictors, with the odds of malignancy increasing by 1.54 (95% confidence interval, 1.16-2.05) for each unit increase in SUV and decreasing by 0.08 (95% confidence interval, 0.03-0.22) if pure. CONCLUSION: In patients with nonlung cancer, in particular colorectal, foci of symmetric and mild uptake limited to the hilar regions that are stable on 2 sequential PET studies despite intervening anticancer therapy are likely related to a benign etiology. PMID: 18765585 [PubMed - as supplied by publisher]
Building a Foundation for Better PET Utilization.
Macapinlac H, Segall G Related Articles Building a Foundation for Better PET Utilization. J Nucl Med. 2008 Sep;49(9):46N-56N Authors: Macapinlac H, Segall G PMID: 18765584 [PubMed - in process]
Nuclear Medicine Communications - Current Table Of Contents
Tumor-specific activation of prodrugs: is there a role for nuclear medicine?
Page: 845DOI: 10.1097/MNM.0b013e3283094efcAuthors: Antunes, Ines F. a; Haisma, Hidde J. b; de Vries, Erik F.J. a
Imaging in cutaneous melanoma.
Page: 847DOI: 10.1097/MNM.0b013e32830439fbAuthors: Ho Shon, Ivan A. a b; Chung, David K.V. c d; Saw, Robyn P.M. d e; Thompson, John F. d e
Guidelines for imaging in cutaneous melanoma.
Page: 877DOI: 10.1097/MNM.0b013e3283043a0cAuthors: Ho Shon, Ivan A. a b; Chung, David K.V. c d; Saw, Robyn P.M. d e; Thompson, John F. d e
PubMed: 1532-6551
Letter to the editor.
Siddiqi S Related Articles Letter to the editor. J Nucl Cardiol. 2008 Sep-Oct;15(5):731; author reply 731-2 Authors: Siddiqi S PMID: 18761278 [PubMed - in process]
Reply.
Einstein AJ, Sanz J, Henzlova MJ, Dellegrottaglie S, Sirol M, Rajagopalan S Related Articles Reply. J Nucl Cardiol. 2008 Sep-Oct;15(5):731-2 Authors: Einstein AJ, Sanz J, Henzlova MJ, Dellegrottaglie S, Sirol M, Rajagopalan S PMID: 18761277 [PubMed - in process]
Noninvasive coronary angiography using multislice computed tomography in a patient with Amplatzer occluder.
Vallejo E, Pelaez JC, Quiroz O, Alcala B, Ramirez-Arias JL Related Articles Noninvasive coronary angiography using multislice computed tomography in a patient with Amplatzer occluder. J Nucl Cardiol. 2008 Sep-Oct;15(5):727-30 Authors: Vallejo E, Pelaez JC, Quiroz O, Alcala B, Ramirez-Arias JL PMID: 18761276 [PubMed - in process]
Sites:
American Board of Nuclear Medicine: The Board advances the health of the public through the establishment and maintenance of standards of training, and education, and the qualification of physicians rendering nuclear medicine services to the people of the United States.American College of Nuclear Physicians: A trade association that represents the interests of nuclear medicine physicians before legislative and regulatory bodies, other medical organizations, the media and general public.
American Society of Nuclear Cardiology: The American Society of Nuclear Cardiology is a professional medical society whose mission is to foster optimal delivery of nuclear cardiology services through professional education and training, the development of clinical guidelines, and the promotion of research.
Australian and New Zealand Society of Nuclear Medicine: About their history, branches, as well as their meetings and publications. Membership forms online.
British Nuclear Medicine Society: The British Nuclear Medicine Society web site gives information on medical events, adverse drug reactions and all other relevant information on nuclear medicine
Clinical Nuclear Medicine: Published monthly, with free abstracts, archived articles, and supscription details.
CNMT: Specializes in finding nuclear medicine jobs for nuclear medicine technologists.
CNR Nuclear Medicine Center: Research institute of the Italian National Research Council, focusing on diagnostic imaging of the central nervous system.
DrSpectScan.com: brain spect scanning and analysis, including before,and after any type of therapy for brain dysfunction. (analyses will be extended to the developing contributionsthat will come via PET and fMRI scanning), all modalities of bra...
European Association of Nuclear Medicine: European Association of Nuclear Medicine, Hollandstrasse 14 / Mezzanine, A-1020 Vienna, Austria Phone, +43 -1 - 2 12 80 30, Fax +43 -1 - 2 12 80 309
Hellenic Society of Nuclear Medicine: Based in Thessaloniki, Greece. Includes the Hellenic Journal of Nuclear Medicine.
History of Positron Imaging: A HISTORY OF POSITRON IMAGING
How Stuff Works: Nuclear Medicine: Nuclear materials get used in many forms of nuclear medicine -- everything from PET scans to chemotherapy uses them! Learn how nuclear medicine works!
Imaginis - Nuclear medicine imaging: Award-winning, breast cancer information and news resource. Imaginis also covers related breast cancer health topics such as hormone replacement therapy (HRT), heart disease, multiple sclerosis, osteoporosis, cervical cancer, and ovarian cancer, as well as, extensive information about medical pr...
Joint Program in Nuclear Medicine: Information on this program from Harvard Medical School.
Nuclear Imaging Westmead: Nuclear Imaging Westmead provides a full range of Nuclear imaging services including traditional radiology and advanced imaging to the health care sector.
Nuclear Medicine Communications: Monthly journal of the BNMS publishing research and clinical work in all areas of nuclear medicine. Submission guidelines and subscription details available.
Nuclear Medicine Information: This site provides information and breaking news about nuclear medicine, PET and related technologies.
Nuclear Medicine jobs: Nuclear Medicine jobs are listed at Physician Employment. You may register to be automatically updated when new jobs are listed.
Nuclear Medicine on the Net: This site features case studies and interactive case forums amongst other physician information resources, and gives a brief history of the topic for the layperson. [Uses Frames]
Nuclear Medicine Research Council: Provides a topical introduction, as well as its use in treating disease and the production and use of radioisotopes.
Nuclear Medicine Technology Resource: Nuclear Medicine Technology Resource WebSite
Positron Emission Tomography: Current and accurate information for patients about Nuclear Medicine, PET. Learn what you might experience, how to prepare for the exam, benefits, risks and more.
Positron Emission Tomography in oncology: Information is provided about the use of dynamic PET, including compartment modeling and parametric imaging, for cancer therapy management.
Radiation Emergency Assistance Center/Training Site: REAC/TS is available 24/7 to provide emergency medical services or advice/consultation related to incidents involving radiological or nuclear materials.
RadiologyInfo: Nuclear Medicine procedure menu
Society of Nuclear Medicine: An international scientific and professional organization founded in 1954 to promote the science, technology and practical application of nuclear medicine.
University of Kansas - Nuclear Medicine: Details about their program and equipment, radiopharamaceutics, quality control, radioimmunoassay and PET. Large collection of clinical and research teaching files.
This directory is based on the Open Directory and may have been modified
